- States wrestle with developing, restricting drones
- Japan marks 3rd anniversary of tsunami disasters
- Ukraine’s Crimea seeks to become independent state
- Ex-Gov. Christie aides to judge: Quash subpoenas
- Rich Peverley collapses on Dallas Stars bench; game postponed
- Al Sharpton, Trayvon Martin’s parents rally against Fla. ‘stand your ground’ law
- Hillary Clinton campaign got illicit funds from D.C. scandal figure
- Obama administration backs off plan to cut prescription-drug program
- Tickets linked to stolen passports purchased by Iranian middleman
- More than 3,500 police planned for Boston Marathon
By David Keene
Conference showed that the values Reagan cherished still endure
Topic - Roy Herbst
New research shows a sharp escalation in the weapons race against cancer, with several high-tech approaches long dreamed of but not possible or successful until now.
The Food and Drug Administration has approved a new Pfizer drug for a subset of lung cancer patients with a particular genetic mutation.
"I'd be very surprised if there wasn't some benefit" on survival, said Herbst, who has consulted for the drug's maker.
Including previously approved targeted therapies, "we have specific therapies now that we can offer for about 18 percent of lung cancer patients that are far superior to chemotherapy and that in many cases can cause their tumors to melt away with few side effects," Herbst said.